health

Pill that mimics Viagra can slow Alzheimer’s progression, study suggests

Pill that mimics Viagra can slow Alzheimer’s progression, study suggests

Experts call trial results of medication that slowed cognitive decline by almost a third ‘very promising’ A pill that mimics Viagra by relaxing blood vessels and increasing blood flow to the brain can slow cognitive decline in people with Alzheimer’s disease by almost a third, a global study suggests. Alzheimer’s is the most common form of dementia, a condition that is forecast to affect 153 million people worldwide by 2050.

Experts call trial results of medication that slowed cognitive decline by almost a third ‘very promising’

A pill that mimics Viagra by relaxing blood vessels and increasing blood flow to the brain can slow cognitive decline in people with Alzheimer’s disease by almost a third, a global study suggests.

Alzheimer’s is the most common form of dementia, a condition that is forecast to affect 153 million people worldwide by 2050. There is currently no cure.

In a stage three trial spanning 13 countries, including the UK, researchers found the tablet AR1001 slowed decline by 31% in patients with early Alzheimer’s disease not receiving any other treatment.

Experts not involved with the study urged caution but said the results were “exciting” and “very promising” and could signal the arrival of a “totally new treatment” for Alzheimer’s.

The findings were presented at the Clinical Trials on Alzheimer’s Disease conference in Boston.

AR1001 is a phosphodiesterase-5 inhibitor and from the same family of medicines as Viagra, which is used to treat erectile dysfunction.

The South Korean company AriBio, which makes AR1001, said the drug slowed decline in 604 people taking no other drugs for Alzheimer’s. In a wider group of patients taking other drugs, the tablet did not achieve statistically significant results.

Prof Tara Spires-Jones, a professor of neurodegeneration at the University of Edinburgh and a fellow at the Academy of Medical Sciences, said the results looked “very promising”.

“This drug acts through boosting blood flow and likely also directly stimulating pathways in brain cells that promote learning and memory,” she said.

Dr Sheona Scales, director of research at Alzheimer’s Research UK, said the findings were “very encouraging”, and marked “an important milestone in the search for new Alzheimer’s treatments”.

AR1001 was “especially interesting” because it was an oral drug that took a “different approach” to existing treatments, she said. “Rather than targeting amyloid, it acts on a specific enzyme and influences several other processes involved in brain function.

“The trial demonstrated a statistically significant slowing of clinical decline in participants who were not taking other commonly used Alzheimer’s medications alongside the trial drug. However, this benefit was not significant across the overall trial group.

“Nonetheless, this is an encouraging development in Alzheimer’s research and reinforces the importance of exploring different approaches to tackling this complex disease.”

Dr Richard Oakley, associate director of research and innovation at Alzheimer’s Society, said: “These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer’s disease that tackles its causes, not just its symptoms.

“AR1001 takes a novel approach, relaxing blood vessels to increase blood flow to the brain. And unlike other disease-modifying treatments that have shown benefit in late-stage trials, it is taken as a once-a-day tablet, which could make treatment simpler.

“Over the year of the trial, this drug was able to effectively slow down people’s decline in memory and thinking by nearly a third, and the side-effects reported were mostly mild to moderate.”

However, the drug did not seem to be as effective for people taking other drugs for Alzheimer’s symptoms, so this needed further investigation, he said.

“AR1001 is from the same family of medicines as Viagra, but it is being developed specifically for Alzheimer’s disease,” said Oakley, adding that people should not take Viagra to try to treat Alzheimer’s.

All the experts called for further trials, and said AR1001 would have to be scrutinised by the scientific community and drug regulatory bodies before it could be prescribed to treat Alzheimer’s.

  • alzheimer
  • pill
  • viagra
  • study
  • progression
  • decline
  • blood
  • people

Summaries and tags are generated automatically. Stay informed with VidiaNews.

Related news

Drinking beer and spirits raises risk of acute kidney damage, study suggests
health

Drinking beer and spirits raises risk of acute kidney damage, study suggests

Research also shows consuming wine could cut risk, reopening debate on whether beverage has health benefits Drinking beer and spirits increases the risk of serious kidney damage, whereas consuming wine offers protection against it, a study suggests. People who drink nine units of spirits a week are 26% more likely to suffer acute kidney injury than those who consume only one unit a week.

Read →
HIDAH Foundation provides free healthcare to children and residents in Dodowa
health

HIDAH Foundation provides free healthcare to children and residents in Dodowa

The HIDAH Humanitarian Foundation has organised a free healthcare outreach at the Home of Taqwa Orphanage in Dodowa, providing medical services to children at the facility and residents of the surrounding community. Speaking at the event, the Founder of HIDAH Humanitarian Foundation, Mujahida Ibrahim Prah, said the initiative was intended to bring essential healthcare closer to people who face difficulties accessing medical services.

Read →
‘Neighbourhood support teams’ to pave way for national care service, Cooper announces
health

‘Neighbourhood support teams’ to pave way for national care service, Cooper announces

Health secretary said programme would help about 566,000 vulnerable people in England by April More than half a million of the most vulnerable people in England will be offered help from joint NHS and social care teams that will pave the way for the promised national care service, Yvette Cooper has announced. Elderly people, care home residents, those with dementia and people near the end of their lives will receive assistance from the new programme.

Read →
Yvette Cooper announces new health support for most vulnerable people in England
health

Yvette Cooper announces new health support for most vulnerable people in England

Health secretary says 500,000 will benefit initially from ‘downpayment’ on PM’s national care service pledge UK politics live – latest updates Half a million of the most vulnerable people in England will get proactive help with their health needs from new teams that will act as a “downpayment” on the promised national care service, Yvette Cooper has announced. Elderly people, care home residents, those with dementia and people near the end of their lives will receive help from new joint teams of NHS and social care staff.

Read →